Preclinical development of Q2361, a transforming new drug for skin cancer prevention in organ transplant recipients [ 1/1/2021 - 12/31/2023 ]

Research Grant

Brief description Patients that receive organ transplants need additional medications in order to prevent organ rejection. Unfortunately, these drugs carry an unwanted side-effect - they permit the development of skin cancer. Currently, other than surgery, little can be done to help these patients. Our preliminary data suggest that a new drug may prevent these skin cancers from forming. This project aims to deliver key insights into the influence of this drug and its role in skin cancer prevention.

Funding Amount $724,957

Funding Scheme Development Grants

Chief Investigator Dr James Wells

Notes Development Grant